Markus Warmuth is President and Chief Executive Officer of Monte Rosa Therapeutics, Inc. (GLUE). The company reported total compensation of $5,032,728 for fiscal year 2025.
| Salary | $650,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $910,080 |
| Option awards | $3,043,648 |
| Non-equity incentive plan | $429,000 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $0 |
| Total | $5,032,728 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Monte Rosa Therapeutics, Inc. filed April 29, 2026, accession 0001193125-26-191439.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $650,000 | $0 | $910,080 | $3,043,648 | $429,000 | $0 | $0 | $5,032,728 |
| FY2024 | President and Chief Executive Officer | $616,400 | $0 | $0 | $1,469,981 | $354,430 | $0 | $0 | $2,440,811 |
Totals as disclosed in each year's own compensation disclosure for Monte Rosa Therapeutics, Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Markus Warmuth this page | President and Chief Executive Officer | $5,032,728 |
| Philip Nickson | Chief Business and Legal Officer | $1,941,781 |
| Filip Janku | Chief Medical Officer | $1,941,781 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Monte Rosa Therapeutics, Inc. compensation brief.
Markus Warmuth's compensation sits inside Monte Rosa Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.